NO20061737L - Aminosubstituerte erylamino B2 adrenergiske receptoragonister - Google Patents
Aminosubstituerte erylamino B2 adrenergiske receptoragonisterInfo
- Publication number
- NO20061737L NO20061737L NO20061737A NO20061737A NO20061737L NO 20061737 L NO20061737 L NO 20061737L NO 20061737 A NO20061737 A NO 20061737A NO 20061737 A NO20061737 A NO 20061737A NO 20061737 L NO20061737 L NO 20061737L
- Authority
- NO
- Norway
- Prior art keywords
- adrenergic receptor
- erylamino
- amino
- substituted
- receptor agonists
- Prior art date
Links
- 239000000048 adrenergic agonist Substances 0.000 title abstract 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 title abstract 2
- 125000003277 amino group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 108060003345 Adrenergic Receptor Proteins 0.000 abstract 1
- 102000017910 Adrenergic receptor Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50568503P | 2003-09-22 | 2003-09-22 | |
| PCT/US2004/030833 WO2005030678A2 (en) | 2003-09-22 | 2004-09-21 | AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20061737L true NO20061737L (no) | 2006-05-31 |
Family
ID=34393055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20061737A NO20061737L (no) | 2003-09-22 | 2006-04-20 | Aminosubstituerte erylamino B2 adrenergiske receptoragonister |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7399863B2 (https=) |
| EP (1) | EP1687257B1 (https=) |
| JP (1) | JP2007505931A (https=) |
| KR (1) | KR20070015496A (https=) |
| CN (1) | CN100465158C (https=) |
| AR (1) | AR046085A1 (https=) |
| AT (1) | ATE428685T1 (https=) |
| AU (1) | AU2004276254A1 (https=) |
| BR (1) | BRPI0414634A (https=) |
| CA (1) | CA2538037A1 (https=) |
| CO (1) | CO5680412A2 (https=) |
| DE (1) | DE602004020655D1 (https=) |
| DK (1) | DK1687257T3 (https=) |
| ES (1) | ES2326172T3 (https=) |
| IL (1) | IL174026A0 (https=) |
| IS (1) | IS8346A (https=) |
| MA (1) | MA28089A1 (https=) |
| MX (1) | MXPA06003093A (https=) |
| NO (1) | NO20061737L (https=) |
| NZ (1) | NZ545764A (https=) |
| PL (1) | PL1687257T3 (https=) |
| PT (1) | PT1687257E (https=) |
| RU (1) | RU2385317C2 (https=) |
| SI (1) | SI1687257T1 (https=) |
| TW (1) | TW200526547A (https=) |
| WO (1) | WO2005030678A2 (https=) |
| ZA (1) | ZA200602308B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| BRPI0511695A (pt) * | 2004-06-03 | 2008-01-08 | Theravance Inc | agonistas de receptor (beta)2 adrenérgico diamina |
| WO2006014704A1 (en) * | 2004-07-21 | 2006-02-09 | Theravance, Inc. | DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS |
| EP1786762A2 (en) * | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
| AU2006205933A1 (en) * | 2005-01-11 | 2006-07-20 | Glaxo Group Limited | Cinnamate salts of a beta-2 adrenergic agonist |
| TWI372749B (en) * | 2005-03-10 | 2012-09-21 | Theravance Inc | Crystalline forms of a biphenyl compound |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| ES2296516B1 (es) | 2006-04-27 | 2009-04-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| ES2302447B1 (es) * | 2006-10-20 | 2009-06-12 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
| US8841304B2 (en) | 2008-01-08 | 2014-09-23 | Array Biopharma, Inc. | Pyrrolopyridines as kinase inhibitors |
| CN101965347B (zh) * | 2008-01-09 | 2013-01-02 | 阵列生物制药公司 | 作为激酶抑制剂的吡唑并吡啶 |
| EP2096105A1 (en) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
| WO2009154557A1 (en) | 2008-06-18 | 2009-12-23 | Astrazeneca Ab | Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders |
| EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| CN112645875A (zh) * | 2020-12-09 | 2021-04-13 | 深圳海王医药科技研究院有限公司 | 一种盐酸丙卡特罗杂质的制备方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US665323A (en) * | 1897-12-15 | 1901-01-01 | Merrell Soule Co | Method of preparing vegetable-soup powders. |
| DE1250450B (de) | 1962-03-31 | 1967-09-21 | Deutsche Gold- und Silber-Scheideanstalt vormals Roessler, Frankfurt/M | Verfahren zur Herstellung von Aminoalkoholen sowie deren Säureadditionssalzen und quartären Ammoniumverbindungen |
| AT310146B (de) * | 1971-04-26 | 1973-09-25 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen |
| CH545764A (https=) | 1971-07-27 | 1974-02-15 | ||
| BE794414A (fr) * | 1972-01-25 | 1973-07-23 | Sandoz Sa | Nouveaux amino-alcools, leur preparation et leur application comme medicament |
| JPS5913510B2 (ja) | 1975-12-26 | 1984-03-30 | オオツカセイヤク カブシキガイシヤ | カルボスチリルユウドウタイノセイゾウホウ |
| JPS5283619A (en) | 1976-01-01 | 1977-07-12 | Yamanouchi Pharmaceut Co Ltd | Alpha-substituted aminomethyl benzyl alcohol derivative |
| JPS609713B2 (ja) | 1976-10-08 | 1985-03-12 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| GB8507942D0 (en) | 1985-03-27 | 1985-05-01 | Beecham Group Plc | Compounds |
| EP0233686A3 (en) | 1986-01-11 | 1989-05-03 | Beecham Group Plc | Bis phenyl ethanol amines and bis phenyoxypropanolamines having a beta-agonist activity |
| US5223614A (en) * | 1987-12-19 | 1993-06-29 | Boehringer Ingelheim Gmbh | New quaternary ammonium compounds, their preparation and use |
| US4894219A (en) * | 1988-03-29 | 1990-01-16 | University Of Florida | Beta-agonist carbostyril derivatives, assay method and pharmacological composition |
| US5434304A (en) * | 1990-09-26 | 1995-07-18 | Aktiebolaget Astra | Process for preparing formoterol and related compounds |
| GB9405019D0 (en) * | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| US6040344A (en) * | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| GB9713819D0 (en) * | 1997-06-30 | 1997-09-03 | Glaxo Group Ltd | Method of reducing the systemic effects of compounds |
| US6713651B1 (en) * | 1999-06-07 | 2004-03-30 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6541669B1 (en) * | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US20020143034A1 (en) * | 1998-12-30 | 2002-10-03 | Fujisawa Pharmaceutical Co. Ltd. | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| US6683115B2 (en) * | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| BR0110331A (pt) * | 2000-04-27 | 2003-01-07 | Boehringer Ingelheim Pharma | Substâncias que mimetizam beta que têm uma atividade de longa duração, processos para prepará-las e o uso das mesmas como medicamentos |
| US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| EP1341759B1 (en) * | 2000-11-10 | 2006-06-14 | Eli Lilly And Company | 3-substituted oxindole beta 3 agonists |
| GB0103630D0 (en) * | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| EP1366025B1 (en) * | 2001-03-08 | 2007-06-27 | Glaxo Group Limited | Agonists of beta-adrenoreceptors |
| JP4143413B2 (ja) * | 2001-03-22 | 2008-09-03 | グラクソ グループ リミテッド | β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体 |
| ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
| US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| US6653323B2 (en) * | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| AU2003222841A1 (en) | 2002-04-25 | 2003-11-10 | Glaxo Group Limited | Phenethanolamine derivatives |
| EP1507754A1 (en) * | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040661A1 (es) * | 2002-07-26 | 2005-04-13 | Theravance Inc | Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2 |
| WO2004101525A1 (en) * | 2003-05-08 | 2004-11-25 | Theravance, Inc. | Crystalline form of aryl aniline beta-2 adrenergic receptor agonist |
| US20040229058A1 (en) * | 2003-05-12 | 2004-11-18 | Trouilhet Yves M. | Multilayer film |
| TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| BRPI0511695A (pt) * | 2004-06-03 | 2008-01-08 | Theravance Inc | agonistas de receptor (beta)2 adrenérgico diamina |
| WO2006014704A1 (en) * | 2004-07-21 | 2006-02-09 | Theravance, Inc. | DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS |
| EP1786762A2 (en) * | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
-
2004
- 2004-09-20 TW TW093128456A patent/TW200526547A/zh unknown
- 2004-09-21 US US10/946,544 patent/US7399863B2/en not_active Expired - Lifetime
- 2004-09-21 CN CNB2004800274097A patent/CN100465158C/zh not_active Expired - Fee Related
- 2004-09-21 AT AT04784634T patent/ATE428685T1/de not_active IP Right Cessation
- 2004-09-21 PL PL04784634T patent/PL1687257T3/pl unknown
- 2004-09-21 EP EP04784634A patent/EP1687257B1/en not_active Expired - Lifetime
- 2004-09-21 DE DE602004020655T patent/DE602004020655D1/de not_active Expired - Lifetime
- 2004-09-21 ES ES04784634T patent/ES2326172T3/es not_active Expired - Lifetime
- 2004-09-21 CA CA002538037A patent/CA2538037A1/en not_active Abandoned
- 2004-09-21 JP JP2006527127A patent/JP2007505931A/ja not_active Withdrawn
- 2004-09-21 AU AU2004276254A patent/AU2004276254A1/en not_active Abandoned
- 2004-09-21 BR BRPI0414634-4A patent/BRPI0414634A/pt not_active IP Right Cessation
- 2004-09-21 DK DK04784634T patent/DK1687257T3/da active
- 2004-09-21 SI SI200431162T patent/SI1687257T1/sl unknown
- 2004-09-21 KR KR1020067005604A patent/KR20070015496A/ko not_active Ceased
- 2004-09-21 PT PT04784634T patent/PT1687257E/pt unknown
- 2004-09-21 RU RU2006113700/04A patent/RU2385317C2/ru not_active IP Right Cessation
- 2004-09-21 MX MXPA06003093A patent/MXPA06003093A/es active IP Right Grant
- 2004-09-21 WO PCT/US2004/030833 patent/WO2005030678A2/en not_active Ceased
- 2004-09-21 NZ NZ545764A patent/NZ545764A/en unknown
- 2004-09-22 AR ARP040103406A patent/AR046085A1/es unknown
-
2006
- 2006-03-01 IL IL174026A patent/IL174026A0/en unknown
- 2006-03-09 IS IS8346A patent/IS8346A/is unknown
- 2006-03-17 CO CO06027355A patent/CO5680412A2/es not_active Application Discontinuation
- 2006-03-20 ZA ZA200602308A patent/ZA200602308B/en unknown
- 2006-04-07 MA MA28922A patent/MA28089A1/fr unknown
- 2006-04-20 NO NO20061737A patent/NO20061737L/no not_active Application Discontinuation
-
2008
- 2008-04-30 US US12/112,726 patent/US7964730B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20061737L (no) | Aminosubstituerte erylamino B2 adrenergiske receptoragonister | |
| NO20056132L (no) | Krystallinsk form av beta2 adrenergisk receptoragonist | |
| NO20063620L (no) | Arylanilinderivater som beta2 adrenergiske receptoragonister | |
| MA29088B1 (fr) | Composes d'indazole-carboxamide. | |
| NO20061074L (no) | Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet | |
| MXPA04004505A (es) | Agonistas del receptor adrenergico beta2 de aril anilina. | |
| NO20072352L (no) | Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet | |
| BR0313233A (pt) | Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica | |
| NO20073664L (no) | Peptider med neuropeptid-2-reseptor (Y2R) agonist aktivitet | |
| BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
| WO2005121065A3 (en) | DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS | |
| NO20100250L (no) | Farmasoytisk preparat som innbefatter en S1P reseptoragonist og en sukkeralkohol, og framgangsmate til fremstilling derav | |
| NO20082445L (no) | Neuropeptid-2 reseptor-agonister | |
| NO331166B1 (no) | Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene | |
| MY139296A (en) | CRYSTALLINE ß2 ADRENERGIC RECEPTOR AGONIST | |
| DK1076644T3 (da) | N-Substituerede aminotetraliner som ligander for neutopeptid Y Y5-receptoren, der er nyttig til behandling af fedme og andre lidelser | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
| NO20060871L (no) | Azepinderivater som farmasoytiske midler | |
| DE602004023946D1 (de) | Kombinationen aus einem arylanilin-beta-2-adrenozeptor-agonisten und einem corticosteroid | |
| DK1506185T3 (da) | Forbindelser og deres anvendelse som 5-HT-inhibitorer | |
| BRPI0507791A (pt) | compostos de indazol-carboxamida como agonistas do receptor 5-ht4 | |
| NO20073113L (no) | Indenylderivater og anvendelse derav for behandling av neurologiske lidelser | |
| DE602006012725D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| DE602005016446D1 (de) | 5-HT4-Rezeptoragonistenverbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |